Table 1.
Characteristics of iVDPV cases.
| Characteristic | Number of cases* (n = 68) | Results |
|---|---|---|
| Gender, % male (n) | 55 | 62% (34) |
| Median age at time of case detection (IQR) | 63 | 1.4 years (0.82, 4.5) |
| Died, % (n) | 58 | 62% (36) |
| Median time between paralysis and death (IQR) | 15 | 0.5 years (0.25, 2.0) |
| Median calculated duration of shedding1 (IQR) | 20 | 1.1 years (0.64, 2.9) |
| Median reported duration of shedding2 (IQR) | 47 | 1.3 years (0.67, 2.0) |
| Median combined duration of shedding3 (IQR) | 67 | 1.3 years (0.67, 2.2) |
| Presented with acute flaccid paralysis, % (n) | 67 | 78% (53) |
| Serotype identified and divergence | 74† | |
| Serotype 1 | ||
| Median percent divergence (IQR) | 15 | 3.2% (2.4, 4.0) |
| Serotype 2 | ||
| Median percent divergence (IQR) | 48 | 2.0% (1.4, 2.3) |
| Serotype 3 | ||
| Median percent divergence (IQR) | 11 | 2.0% (1.3, 2.2) |
| Immune disorder | 68 | |
| Predominantly antibody immunodeficiency, % | 39 | 57% |
| Combined Immunodeficiency, % | 15 | 22% |
| Primary immunodeficiency (other), % | 1 | 1.5% |
| Primary immunodeficiency (unspecified), % | 13 | 19% |
This table describes characteristics of iVDPV cases included in our analysis.
Only cases with available information were analyzed for each parameter. Duration of shedding was recorded according to the following definitions:
Calculated as the time from last OPV administration to last positive stool sample.
As reported by author of original case report.
Combined calculated and reported values.
There were more serotypes detected than cases because 6 iVDPVs had multi-serotype infections.
Immune disorders were categorized as follows: predominantly antibody deficiency = agammaglobulinemia, hypogammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, or other antibody deficiency; combined immunodeficiency = severe combined immunodeficiency, major histocompatibility complex class II deficiency, human leukocyte antigen deficiency; primary immunodeficiency-other = immune disorders that either did not fall into the previous categories; or primary immunodeficiency-not specified = cases whose immune disorders were not specified by the authors.